Replies to post #193951 on Biotech Values

[DewDiligence]

BNTC IPOs 1.725M* ADRs @$9.21 and 575K* “pre-funded” warrants* exercisable at $5.50/sh:

http://finance.yahoo.com/news/benitec-announces-pricing-initial-public-123000159.html

I don’t think much of BNTC’s lead program in HCV (#msg-115831950) and would recommend avoiding these shares.

Each ADR is equivalent to 20 ordinary (Australian) shares.

*Assuming exercise of underwriter’s option.

[ddRNAi2014]

DewDiligence: What if it serves as a Proof of Concept. Most investors already hold the view that it is not going to be a commercial product but will be the springboard for the pipeline-HBV, WetAMD, NSCLC, there is no disease that it couldn't be used for in theory.

[DewDiligence]

BNTC’s AASLD late-breaker should dispel notion that LB status means content is consequential:

http://finance.yahoo.com/news/benitec-biopharmas-abstract-accepted-presentation-120000213.html

[DewDiligence]

BNTC dumps CEO:

http://finance.yahoo.com/news/greg-west-benitecs-chief-financial-220500638.html

They should dump their HCV drug too (#msg-115831950).

[DewDiligence]

BNTC abandons HCV program:

http://finance.yahoo.com/news/tt-034-hepatitis-c-clinical-234200736.html

I predicted this some time ago (#msg-115831950).